(P131) Improved Prostate Delineation in Prostate HDR Brachytherapy With TRUS-CT Deformable Registration Technology

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

We have developed a novel TCDR-based approach to improve prostate delineation utilizing intraoperative TRUS-based prostate volume in prostate HDR brachytherapy and demonstrated its improvement in prostate volume accuracy over the standard CT-defined prostate volumes. Integration of TRUS into the HDR brachytherapy treatment planning workflow has the potential to enable accurate dose planning and delivery and enhance prostate HDR treatment outcome.

Xiaofeng Yang, Peter Rossi, MD, Ashesh Jani, MD, Hui Mao, PhD, Tomi Ogunleye, Walter J. Curran, Tian Liu; Emory University

PURPOSE: The main challenge for computed tomography (CT)-based prostate high-dose-rate (HDR) treatment planning is to accurately define prostate volume in CT images due to the poor soft-tissue contrast. To address this issue, we have developed a novel approach that integrates intraoperative transrectal ultrasound (TRUS)-based prostate volume into HDR treatment planning through TRUS-CT deformable registration (TCDR) based on the catheters. This study’s purpose is to assess the clinical feasibility of the TCDR-based approach and compare its performance with the standard physician’s CT contours in the setting of HDR prostate brachytherapy.

METHODS: To improve prostate contour accuracy, the proposed TCDR-based approach utilizes two unique features in the HDR procedures: (1) Accurate prostate volume obtained from three-dimensional (3D) TRUS images-during HDR procedure, 3D TRUS images of the prostate are acquired with 1- or 2-mm step size right after the catheters are inserted. (2) Accurate TRUS-CT image registration using HDR catheters-both TRUS and CT images are obtained after the catheter insertions.

The catheters are reconstructed on the TRUS and CT images and subsequently used as landmarks for the TRUS-CT image registration using a fuzzy-to-deterministic algorithm. The intraoperative TRUS-based prostate volume is then deformed to the CT image to obtain the CT prostate volume, which is used for HDR treatment planning. In a pilot study, 16 prostate HDR brachytherapy procedures were evaluated retrospectively. CT-based prostate volumes were contoured by two experienced physicians. Both TCDR-based prostate volume and the standard CT-based prostate volumes are compared with the MRI-defined prostate contours (gold standard). A t-test was used to examine the significance of the difference between the two physicians’ CT-based contours, the TCDR-defined contours, and the MRI-defined prostate volumes.

RESULTS: A 20% to 40% improvement in prostate volume accuracy can be achieved with the TCDR-based approach as compared with the standard CT-based prostate volumes. TCDR-defined prostate volumes match closely to the MRI-defined prostate volumes (mean difference: 0.9 ± 7.3%; P = .54). CT-based contours assessed by the two physicians overestimated the size of the prostate gland by 7.3% (7.3 ± 18.7%) and 59.7% (59.7 ± 37.8%) and were associated with significant variability, even between these two experienced physicians (P < .01).

CONCLUSIONS: We have developed a novel TCDR-based approach to improve prostate delineation utilizing intraoperative TRUS-based prostate volume in prostate HDR brachytherapy and demonstrated its improvement in prostate volume accuracy over the standard CT-defined prostate volumes. Integration of TRUS into the HDR brachytherapy treatment planning workflow has the potential to enable accurate dose planning and delivery and enhance prostate HDR treatment outcome.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Related Content